Cellares Partners with ProTgen on Automated T Cell Therapy Manufacturing

• Cellares and ProTgen have entered a partnership to automate manufacturing and quality control for ProT-096, a personalized progenitor T cell therapy for refractory leukemia and other hematologic malignancies.

• The agreement also includes regulatory support from Cellares for ProTgen’s Investigational New Drug application preparation.

Cellares and ProTgen have announced a partnership focused on automating manufacturing and quality control processes for ProT-096, ProTgen’s personalized progenitor T cell therapy being developed for patients with refractory leukemia and other hematologic malignancies.

According to the companies, the collaboration will combine ProTgen’s targeted Notch activator technology with Cellares’ automated cell therapy manufacturing platform. Cellares will also provide regulatory support to assist ProTgen in preparing an Investigational New Drug application for the therapy.

The companies stated that ProT-096 is designed to restore long-term immune protection in patients whose immune systems have been compromised following treatment for hematologic cancers. They added that scalable and reproducible manufacturing is necessary to support clinical development and potential commercial production of the therapy.

“Cellares’ fully automated, GMP-ready manufacturing platform is designed to support the efficient development of cell therapy treatments for patients with significant unmet medical need.”

Carter Cliff, Chief Executive Officer of ProTgen

Cellares said its Cell Shuttle and Cell Q technologies are intended to reduce manual intervention, standardize manufacturing processes, and support clinical- and commercial-scale GMP production. The company added that the partnership expands its automated manufacturing platform across additional cell therapy modalities, including personalized progenitor T cell therapies, alongside existing CAR-T and hematopoietic stem cell programs.